TCGX Acquisition

Where it stands

Searching · next dated event 6 August 2028

Outside date — not a date on which you can claim cash.

Merging with

No target announced — still searching.

Industry

Healthcare

What it set out to buy: Healthcare

Deal value

not stated in the filings we hold

Price vs cash floor

$13.75 vs $10.00

$3.75 above the last filed cash held for you; 37.0% above cash against our estimated ~$10.04

Cash left in trust

not yet extracted into a snapshot — the filings below may state it

IPO

5 August 2026

$75M raised · 100.0% of each $10 unit into trust

Headquarters

UGLAND HOUSE, GRAND CAYMAN, 94301

registered in the Cayman Islands

Lead underwriter

Jefferies LLC

Key officers

Yu Chen-Ming (Chief Executive Officer) · Skaling Craig David (Chief Financial Officer) · Cheng Andrew (Director)

Listed securities

TCGX common · TCGX common $13.76

1. No dated redemption election is on file for this name. That is an absence in the record, not proof that the right has gone — but it does mean this page cannot tell you a day to act by.
2. Cash held in trust is $10.00 per share as last filed. That is the figure a redemption pays out at, plus whatever interest the trust earns between the filing and the window.
3. The charter runs to a date no filing we hold states; from the IPO date and the charter term we estimate 5 August 2028. Whenever it falls, if no deal closes by then the trust is returned to holders — a floor of a different kind: it pays out, but you do not choose when, and this one you should read out of the prospectus yourself.

1. 5 August 2026IPOpassed

   $75M raised into trust

2. 6 August 2028Outside date0001193125-26-347043

• 8-K12 August 20260001193125-26-347043

  For investors monitoring redemption parameters and trust preservation, this filing confirms the baseline $10.00-per-share trust deposit, fixes the expiration timeline, and codifies the sponsor’s indemnity obligation to replace any trust shortfall caused by third-party claims down to $10.00 per share or the actual trust value, whichever is lower, per the registrant’s disclosure. The 80% fair market value threshold for target acquisitions, the automatic conversion mechanics for the 2,156,250 founder shares, and the sponsor’s forfeiture release following full over-allotment exercise establish control and dilution baselines. The disclosed $3,000,000 convertible working capital facility and separate $20,000,000 forward purchase commitment indicate structured backstop financing, while the auditor’s opinion and detailed liability schedule (including $593,193 in accrued offering costs, $32,232 due to related parties, $58,725 in accrued expenses, and a $164,244 related-party promissory note) allow investors to verify operational runway outside the trust. The filing attributes all target search risks, including geopolitical instability, inflation, and supply chain disruptions, directly to management’s acknowledgment that no assurance exists of completing a combination within the 24-month window. As stated in the notes, management has confirmed the company generated zero operating revenues as of August 6, 2026, and will only generate non-operating interest income until a business combination closes. The document identifies Chen Yu, M.D., M.B.A., as Chief Executive Officer and signatory, and WithumSmith+Brown, PC as the independent registered public accounting firm providing audit assurance.

• 424B46 August 20260001193125-26-336098

  A share-only SPAC has no warrant and no right, so there is no strike, expiry or warrant redemption trigger to record: the absence is the design and is stated on the cover, not a reading failure. Sponsor economics are unusually explicit - founder shares were acquired for $25,000 in aggregate, approximately $0.011594 per share, against the $10.00 public price. The $3,000,000 of deferred underwriting is held in the trust itself. The completion window is 24 months from closing, and Odyssey Transfer rather than Continental acts as trustee.

• 8-K6 August 20260001193125-26-338268

  This filing establishes the baseline SPAC structure: trust per share is $10.00, redemption deadline is 24 months, and the company is now searching for a target in healthcare/life sciences. The forward purchase agreement provides a potential $20 million backstop at the time of a deal, but is contingent on investment committee approval. Sponsor conduct is standard: sponsor purchased private placement shares, founder shares are subject to a one-year lock-up after a business combination (or earlier if $12.00 price target met), and private placement shares are locked up for 30 days. The company has no warrants, which is atypical. The IPO is fully subscribed with the over-allotment exercised, indicating strong initial demand.

• S-1/A31 July 20260001193125-26-328576

  This amendment materially establishes the economic alignment and liquidity parameters that will govern shareholder redemption calculus and de-SPAC transaction feasibility. By codifying the sponsor’s post-IPO equity range between 19.0% and 22.1%, the filing quantifies the downside risk sponsors face if public holders redeem, a metric investors routinely weight when assessing whether a future business combination will proceed at current market valuations or trigger forced terminations. The explicit attestation that officers and directors have waived all rights, title, interest, or claims against the trust account reinforces trust protection mechanics, clarifying that any indemnification payouts must originate from off-trust corporate funds or require successful consummation of an initial business combination. The inclusion of a Forward Purchase Agreement with Fund III signals pre-committed anchor capital that may serve as a de-SPAC backstop, potentially mitigating the pressure on public shareholder retention. Furthermore, the consent letters from Andrew Cheng, M.D., Ph.D., Ying Huang, Ph.D., and Wei Lin, M.D., paired with the SEC’s internal classification notation identifying the CF Office as 03 Life Sciences, indicate management’s sector concentration, though the filing discloses no specific target company, revenue forecasts, market size data, strategic roadmap, patent portfolios, partnership terms, litigation exposure, or accelerated redemption timelines. The $1,000,000 in estimated offering expenses also delineates the non-trust cash reserve available to fund continued search activities prior to merger completion.

• S-120 July 20260001193125-26-308950

  This filing is the foundational document for the SPAC, detailing the terms that will govern its lifecycle. The nominal sponsor cost creates significant dilution for public shareholders (sponsor's founder shares cost ~$0.0116 vs. $10.00 public price). The forward purchase agreement provides a backstop of $20 million for a business combination but is subject to investment committee approval, adding uncertainty. The focus on healthcare and China-based targets introduces specific regulatory and geopolitical risks. The independent directors have strong biotech backgrounds, which may aid deal sourcing. The absence of warrants reduces dilution but may affect investor demand. The 24-month deadline and redemption mechanics are standard. The trust value of $10.00 per share is the baseline for redemptions. The filing discloses extensive conflicts of interest, including the sponsor's incentive to complete a deal quickly. The S-1 must be declared effective before the IPO can proceed.

• DRS23 June 20260001193125-26-278885

  These terms define the operational countdown for target acquisition, lock in the liquidation floor for public investors, and calibrate the financial incentives of insiders versus public shareholders. The prospectus notes that because the sponsor acquired founder shares for $25,000 overall (approximately $0.011594 per share), executive officers and directors face significant personal financial loss if no deal closes, creating a strong incentive to complete any transaction, potentially one that later declines in value.

• SCHEDULE 13G13 August 20260001346824-26-000226

  What changed: Schedule 13G Joint Filing Agreement (routine compliance exhibit). The Filers—RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P.—executed a joint filing agreement dated August 13, 2026, to collectively report beneficial ownership of TCGX Acquisition Corp.’s Class A Ordinary Shares (par value $0.0001 per share) pursuant to Securities Exchange Act Rule 13(d)(1)(k). The agreement consolidates future disclosure routing for these four parties and stipulates that either party may terminate the arrangement upon one week’s prior written notice. No modifications to the trust account, redemption mechanics, proposed business combination deadline, or sponsor governance are recorded in the text. Why it matters: This routine compliance filing streamlines Section 13(d) reporting obligations for the named investment vehicles and principals, reflecting coordinated position tracking while leaving the SPAC’s SEARCHING status and underlying capital structure unaltered. The document contains no claims regarding prospective target companies, customer pipelines, revenue metrics, market sizing, strategic initiatives, technology platforms, partnership arrangements, pending litigation, or personnel changes. All enumerated terms—including the $0.0001 par value designation and the one-week termination notice period—are attributable directly to the Filers as submitted to the United States Securities and Exchange Commission.

• 8-K12 August 20260001193125-26-347043

  What changed: Form 8-K Current Report disclosing the consummation of an initial public offering and simultaneous private placement, accompanied by an audited balance sheet and notes to financial statements. According to the registrant, the company closed its initial public offering on August 6, 2026, selling 8,625,000 Class A ordinary shares at $10.00 per share, generating $86,250,000 in gross proceeds, including the full exercise of a 1,125,000-share over-allotment option. Simultaneously, the company consummated a private placement of 522,500 shares at $10.00 per share for $5,225,000, of which TCGX Sponsor, LLC purchased 436,250 shares and Jefferies LLC purchased 86,250 shares. The filing states that $86,250,000 ($10.00 per public share) was placed in a trust account with Odyssey Transfer and Trust Company acting as trustee. The document establishes a 24-month completion window for a business combination from the closing date. Shareholders may redeem shares for a pro rata portion of the trust account (initially $10.00 per share) calculated two business days prior to a combination, subject to a 15% aggregate redemption cap per shareholder without written consent if the company conducts redemptions outside standard tender offer rules. In the event of liquidation, the filing notes up to $100,000 of trust interest may fund dissolution expenses, and the underwriters have agreed to waive their $3,450,000 deferred underwriting commission. The filing also reports a $20,000,000 forward purchase agreement for 2,000,000 shares at $10.00 each and discloses an audited balance sheet showing $3,500,000 in cash, $86,250,000 in the trust account, $4,298,394 in total liabilities, and a $(723,394) shareholders’ deficit as of August 6, 2026. Why it matters: For investors monitoring redemption parameters and trust preservation, this filing confirms the baseline $10.00-per-share trust deposit, fixes the expiration timeline, and codifies the sponsor’s indemnity obligation to replace any trust shortfall caused by third-party claims down to $10.00 per share or the actual trust value, whichever is lower, per the registrant’s disclosure. The 80% fair market value threshold for target acquisitions, the automatic conversion mechanics for the 2,156,250 founder shares, and the sponsor’s forfeiture release following full over-allotment exercise establish control and dilution baselines. The disclosed $3,000,000 convertible working capital facility and separate $20,000,000 forward purchase commitment indicate structured backstop financing, while the auditor’s opinion and detailed liability schedule (including $593,193 in accrued offering costs, $32,232 due to related parties, $58,725 in accrued expenses, and a $164,244 related-party promissory note) allow investors to verify operational runway outside the trust. The filing attributes all target search risks, including geopolitical instability, inflation, and supply chain disruptions, directly to management’s acknowledgment that no assurance exists of completing a combination within the 24-month window. As stated in the notes, management has confirmed the company generated zero operating revenues as of August 6, 2026, and will only generate non-operating interest income until a business combination closes. The document identifies Chen Yu, M.D., M.B.A., as Chief Executive Officer and signatory, and WithumSmith+Brown, PC as the independent registered public accounting firm providing audit assurance.

• SCHEDULE 13G12 August 20260000921895-26-002072

  What changed: A routine compliance exhibit consisting of a Joint Filing Agreement attached to a Schedule 13G beneficial ownership report for TCGX Acquisition Corp., executed on August 12, 2026, by multiple Biotechnology Value Fund affiliates and Mark N. Lampert pursuant to Rule 13d-1(k)(1). Nothing changed regarding your tracking parameters. The filing contains zero commentary on redemption deadlines, trust value per share, extension proceedings, business combination progress, or sponsor conduct. It merely consolidates existing beneficial ownership disclosures into a single joint submission. Why it matters: According to the jointly filed agreement, Mark N. Lampert serves as the authorized signatory for the listed Biotechnology Value Fund entities regarding their aggregate holdings of TCGX Acquisition Corp. Class A ordinary shares, which carry a par value of $0.0001 per share. While the filers’ arrangement asserts compliance with Rule 13d-1(k)(1) to streamline filings under the 1934 Act, the document provides no data on the announced deadline, any proposed trust adjustments, or operational developments. Investors receive no update on whether the sponsor intends to seek an extension, liquidate, or pursue a target.

• 424B46 August 20260001193125-26-336098

  What changed: Priced IPO of Class A ordinary shares - not units - at $10.00, raising $75,000,000, with a 45-day over-allotment option for up to 1,125,000 additional shares. The prospectus states that, unlike certain other special purpose acquisition company offerings, investors in this offering will not receive warrants. Trust: $75,000,000, or up to $86,250,000 with full over-allotment, at $10.00 per share, with Odyssey Transfer and Trust Company as trustee. Underwriting is $0.60 per share ($4,500,000), of which $0.40 per share ($3,000,000, up to $3,450,000) is deferred. Why it matters: A share-only SPAC has no warrant and no right, so there is no strike, expiry or warrant redemption trigger to record: the absence is the design and is stated on the cover, not a reading failure. Sponsor economics are unusually explicit - founder shares were acquired for $25,000 in aggregate, approximately $0.011594 per share, against the $10.00 public price. The $3,000,000 of deferred underwriting is held in the trust itself. The completion window is 24 months from closing, and Odyssey Transfer rather than Continental acts as trustee.

• 3/A6 August 20260001193125-26-338388

  What changed: Routine compliance exhibit: An amended Form 3 insider ownership report for TCGX Acquisition Corp. According to the filing, Chief Executive Officer and 10% owner Yu Chen-Ming and 10% owner TCGX Sponsor, LLC submitted no updates, as the amendment explicitly states there were “No non-derivative transactions or holdings reported.” Neither the sponsor nor the chief executive bought, sold, or structurally repositioned their beneficial shares between filings. Why it matters: For investors monitoring redemption calendars, trust value preservation, extension votes, and deal execution mechanics, this submission delivers no new guidance on capital deployment, unit conversion parameters, or shareholder voting thresholds. The document contains zero claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel movements beyond the two named principals. By confirming that the sponsor and chief executive maintained a static equity posture, the filing removes near-term speculation around insider distribution pressure while the vehicle remains in search status. Because no transactional activity occurred, sponsor conduct signals neither aggressive accumulation nor defensive liquidation ahead of a potential combination or trust wind-down.

At-risk capital: $4.4M — 425,000 private placement shares, bought at the IPO and worthless if the company liquidates. This is what the sponsor itself loses if no deal closes. per the prospectus (424B4 0001193125-26-336098)